Beijing Tongrentang Valuation Multiples

Beijing Tongrentang Overview

About Beijing Tongrentang

Beijing Tongrentang Co Ltd is a China-based company operating in the traditional Chinese medicinal industry. The company produces modern pharmaceuticals and operates retail businesses and medical services. The company's main products consist of Liuwei Dihuang series, Tongren Dahuoluo series, Tongren Niuhuang Qingxin series, Angong Niuhuang series, and Donkey-hide gelatin series. It distributes its products under the brand of Tongrentang.

Founded

1997

HQ

Employees

17.9K

Website

gf.tongrentang.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $3B

EBITDA: $374M

EV

$4B

Valuation Multiples

Multiples.vc

Start free trial

Beijing Tongrentang Financials

Beijing Tongrentang reported last 12-month revenue of $3B and EBITDA of $374M.

In the same LTM period, Beijing Tongrentang generated $1B in gross profit, $374M in EBITDA, and $182M in net income.

Beijing Tongrentang P&L

In the most recent fiscal year, Beijing Tongrentang reported revenue of $3B and EBITDA of $470M.

Beijing Tongrentang expects next 12-month revenue of XXX and NTM EBITDA of XXX

Beijing Tongrentang Stock Performance

Beijing Tongrentang has current market cap of $6B, and enterprise value of $4B.

Beijing Tongrentang's stock price is $4.07.

Beijing Tongrentang Valuation Multiples

Beijing Tongrentang trades at 1.8x EV/Revenue multiple, and 12.0x EV/EBITDA.

Beijing Tongrentang Financial Valuation Multiples

As of April 21, 2026, Beijing Tongrentang has market cap of $6B and EV of $4B.

Equity research analysts estimate Beijing Tongrentang's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Beijing Tongrentang has a P/E ratio of 30.6x.

Beijing Tongrentang Margins & Growth Rates

Beijing Tongrentang's revenue in the last 12 month grew by 6%.

Beijing Tongrentang's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.

Beijing Tongrentang's rule of 40 is 21% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Beijing Tongrentang's rule of X is 29% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Beijing Tongrentang Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Beijing Tongrentang M&A Activity

Beijing Tongrentang acquired XXX companies to date.

Last acquisition by Beijing Tongrentang was on XXXXXXXX, XXXXX. Beijing Tongrentang acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Beijing Tongrentang Investment Activity

Beijing Tongrentang invested in XXX companies to date.

Beijing Tongrentang made its latest investment on XXXXXXXX, XXXXX. Beijing Tongrentang invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).